SCHEMBL3255189

SCHEMBL3255189

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(NS(=O)(=O)c4ccc(C(C)(C)C)cc4)cc3c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.55
HIF1A Q16665 5/20 0.54
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTPN5 P54829 1/20 0.43
MAPT P10636 3/20 0.42
LMNA P02545 3/20 0.42
TP53 P04637 2/20 0.42
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249004 0.91 HIF1A (0.51) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3251191 0.90 PKM (0.49) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3254022 0.90 HIF1A (0.52) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3251174 0.90 HIF1A (0.52) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3255461 0.90 BRD4 (0.52) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3254000 0.89 LMNA (0.53) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3254038 0.89 BRD4 (0.55) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3252062 0.89 MEN1 (0.50) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3242688 0.88 BRD4 (0.60) BRD4HIF1AMEN1KMT2AALDH1A1
SCHEMBL3244769 0.87 HIF1A (0.54) BRD4HIF1AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 BRD4 545/4885HIF1A 974/4885MEN1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.